Most of us, doctors use to
have a preexisting suggestion set on our mind backed up by some incomplete data
that, “Aspirin might have some role in primary prevention” (treating high risk patients
with it before development of the disease, eg: Elderly patient with Diabetes,
Hypertension, Dyslipidemia or Family history of Cardiovascular diseases but no
prior Heart attack or stroke)
Current
data: Over the last month, more that few clinical trials (ASPREE, ASCEND Trial,
Arrive Study, Papers from NEJM) suggested by their data analysis, that aspirin
has no role in primary prevention. Moreover, they might be linked with slightly
higher mortality rate (higher association with ? Cancer, only one clinical
study suggested that thought, further studies are required for confirmation).
How
to put this evidence in clinical use: Based on the current data, we might be
able to shift our treatment plan for high risk patients to control the risk
factors like diabetes, hypertension & dyslipidemia and life style
modifications rather than putting them on aspirin at the beginning (Not so
uncommon). These strategies have proven benefits on primary prevention.
So,
Aspirin to be provided as a part of secondary prevention (patient with
existing/history of CVD), but not as a part of primary prevention plan.
Contents
are collected from: (Medscape: https://go.spyluv.com/2xJ7Xk3
, https://go.spyluv.com/2xKZsEX ,
NEJM: https://go.spyluv.com/2I8d8Pm
)
